GC
DMK

Globeflex Capital’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Globeflex Capital’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed – – 558
2016
Q2 		$0 Buy
+1
New +$461 ﹤0.01% 535

Other funds holding DMK

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $286M AUM 26.75% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Globeflex Capital's DMK Position: Q3 2016 in Review

Globeflex Capital sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2016, closing a stake of 1 share.

Globeflex Capital first reported a position in DMK in Q2 2016 and held it in 1 quarter. The position peaked at $0 in Q2 2016. 37 funds tracked by Wall St. Rank hold DMK as of Q3 2016.

  • Globeflex Capital reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2016 after selling out during the quarter.
  • Globeflex Capital sold 1 DMK Pharmaceuticals Corporation Common Stock share in Q3 2016.
  • Globeflex Capital first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2016 and held it in 1 quarter.
  • Globeflex Capital's DMK Pharmaceuticals Corporation Common Stock position peaked at $0 in Q2 2016.
  • 37 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2016.

Based on Globeflex Capital's 13F filing for Q3 2016, filed 9 Nov 2016.